Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| IDI-20190983 | Other Grant/Funding Number | Centro de Transferencia Tecnológica - UGR |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hospital Universitario Reina Sofia de Cordoba | OTHER_GOV |
| Maimónides Biomedical Research Institute of Córdoba | OTHER |
Not provided
Not provided
Not provided
Not provided
This study aims to evaluate the effect of the enriched extra virgin olive oil spread in plant sterols from the olive itself and demonstrate its effect anticholesterolemic and cardioprotective in children and adolescents with hypercholesterolemia.
A clinical study of nutritional intervention, randomized with double blind, adjusted by randomization blocks that consider age and sex, and crossover of 2 months duration each period, with 1-month washout period, in 50 subjects (25 per randomization group). The study will be carried out in the Reina Sofía Universitary Hospital of Córdoba, as well as at the Institute of Nutrition and Food Technology of the University of Granada.
The effects of the enriched spread in patients on the lipid profile will be evaluated plasma and its action on biomarkers of cardiovascular risk and on the microbiota intestinal depending on the specific genotype of each subject. In addition, the presence of minor olive oil compounds present in plasma (metabolomic analysis). In this way, at the end of the project, scientific information will be available contrasted on the enriched product and its effects on cardiovascular protection, in addition to its palatability and acceptance.
The main objective is to evaluate the effect of the enriched extra virgin olive oil spread in plant sterols from the olive itself and demonstrate its effect anticholesterolemic and cardioprotective in children and adolescents with hypercholesterolemia.
As specific objectives will be determined:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Enriched spread | Experimental | Children between 20-40 kg will receive a dose of 15 g of the spread (1.2 g/d of plant sterols: 0.06-0.03 g/kg of weight/d) and those with a weight between 40-60 kg will receive two doses of 15 g of the spread (2.4 g/d of plant sterols: 0.06-0.04 g/kg of weight/d) |
|
| Control spread | Placebo Comparator | Children between 20-40 kg will receive a dose of 15 g of the spread (1.2 g/d of plant sterols: 0.06-0.03 g/kg of weight/d) and those with a weight between 40-60 kg will receive two doses of 15 g of the spread (2.4 g/d of plant sterols: 0.06-0.04 g/kg of weight/d) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enriched spread | Dietary Supplement | The experimental spread is made with a base made with 90% extra virgin olive oil to which plant sterols are added. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Hypercholesterolemia | Assessing changes of plasma lipids levels from the baseline to the end of each treatment. The serum concentrations of total cholesterol (mg/dL), triglycerides (TG, (mg/dL)), high-density lipoprotein cholesterol (HDLc, (mg/dL)), and low-density lipoprotein cholesterol (LDLc, (mg/dL)), apolipoprotein A1 (Apo-A1, (mg/dL)) and apolipoprotein B (Apo-B, (mg/dL)) will be analyzed by spectrophotometry. | Month 0; Month 2; Month 3; Month 5 |
| Measure | Description | Time Frame |
|---|---|---|
| Body composition | Assessing changes of body composition from the baseline to the end of each treatment. To obtain data on body composition, fat mass (kg), lean mass (kg) and total body water (kg) will be measured via bioimpedance technology using TANITA MC-780MA (Tokyo, Japan). | Month 0; Month 2; Month 3; Month 5 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| MARÍA DOLORES MESA GARCÍA | Universidad de Granada | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Universitario Reina Sofia de Córdoba | Córdoba | 14004 | Spain | |||
| Universidad de Granada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 41241688 | Derived | Garcia-Perez P, Vazquez-Aguilar A, Sanchez-Rodriguez E, Jurado-Castro JM, Pastor-Villaescusa B, Gil-Campos M, Rangel-Huerta OD, Gil A, Aguilera CM, Mesa MD, Rocchetti G, Lucini L. Chemometrics-guided plasma lipidomics insights underlying the decrease of plasma total cholesterol and LDLc in children with hypercholesterolemia following habitual intake of an EVOO-based phytosterols-enriched spreadable cream. Metabolomics. 2025 Nov 15;21(6):169. doi: 10.1007/s11306-025-02368-3. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006937 | Hypercholesterolemia |
| ID | Term |
|---|---|
| D006949 | Hyperlipidemias |
| D050171 | Dyslipidemias |
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Control spread | Dietary Supplement | The control spread will be the same base spread made with extra virgin olive oil without the added plant sterols. |
|
| Body composition percentages |
Assessing changes of body composition percentages from the baseline to the end of each treatment. To obtain data on body composition, fat mass (percent), lean mass (percent) and total body water (percent) will be measured via bioimpedance technology using TANITA MC-780MA (Tokyo, Japan). |
| Month 0; Month 2; Month 3; Month 5 |
| Systolic blood pressure | Assessing changes of Systolic Blood Pressure from the baseline to the end of each treatment. | Month 0; Month 2; Month 3; Month 5 |
| Diastolic blood pressure | Assessing changes of Diastolic Blood Pressure from the baseline to the end of each treatment. | Month 0; Month 2; Month 3; Month 5 |
| Oxidation biomarkers | Assessing changes of oxidized LDL from the baseline to the end of each treatment, by using an ELISA kit | Month 0; Month 2; Month 3; Month 5 |
| Enzymatic antioxidant status | Assessing changes on erythrocyte antioxidant enzymes (catalase, superoxide dismutase, glutathione peroxidase and glutathione reductase) from the baseline to the end of each treatment, by using spectrophotometric kits. | Month 0; Month 2; Month 3; Month 5 |
| Non-enzymatic antioxidant status | Assessing changes on plasma liposoluble antioxidants (retinol, beta-carotene and Q-coenzyme) from the baseline to the end of each treatment, by HPLC. | Month 0; Month 2; Month 3; Month 5 |
| Endothelial function status | Assessing changes on plasma endothelin-1 from the baseline to the end of each treatment, by using an ELISA kit. | Month 0; Month 2; Month 3; Month 5 |
| Endothelial damage | Assessing changes on plasma VCAM , ICAM-1, E-selectin and mielopeoxidasa from the baseline to the end of each treatment, by Luminex xMAP technology. | Month 0; Month 2; Month 3; Month 5 |
| Fecal microbiome | Assessing changes of fecal microbiome profile from the baseline to the end of each treatment. Stool DNA will be isolated with the QIAamp DNA stool mimi kit. Amplification of variable region V3-V1 of 16S gen will be sequenced using the Illunina Next Generation Sequencing MiSeg. | Month 0; Month 2; Month 3; Month 5 |
| Plasma metabolomic analysis | A liquid chromatography platform coupled to a spectrophotometer will be used mass (LC/MS) to determine plasma metabolic profiles by targeted analyses from the baseline to the end of each treatment. | Month 0; Month 2; Month 3; Month 5 |
| Urine metabolomic analysis | A liquid chromatography platform coupled to a spectrophotometer will be used mass (LC/MS) to determine urine metabolic profiles by targeted analyses from the baseline to the end of each treatment. | Month 0; Month 2; Month 3; Month 5 |
| Granada |
| 18071 |
| Spain |
| D009750 |
| Nutritional and Metabolic Diseases |